Decnupaz FDA Approval: First CD123 ADC for BPDCN Therapy
Review the May 2026 FDA approval of Decnupaz (pivekimab sunirine), the first CD123-targeted ADC for BPDCN. Explores clinical efficacy and launch strategies.
Back to Articles
Articles tagged with “cd123-adc”